Dr. Prayoon Prabharasuth, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2594 William St, Newfane, NY 14108 Phone: 716-778-7118 Fax: 716-778-7119 |
News Archive
‘Last mile' transportation and subsequent user storage conditions present unique challenges when it comes to ensuring the safe and effective use of pharmaceutical products. Berlinger & Co. AG, a market leader in pharmaceutical temperature monitoring, has released a White Paper entitled "Beyond the Cold Chain" that discusses the temperature-related problems associated with the delivery and storage of drugs after they leave the primary supply chain.
Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its recently launched pain reliever, Cobroxin, was selected as the "Best New Product" at the Efficient Collaborative Retail Marketing (ECRM) Conference. Cobroxin was chosen as the award recipient by conference attendees, including several of the leading national retailers.
Abbott Pharmaceuticals has announced the withdrawal of weight loss drug Meridia from shelves in the United States and urged patients to stop taking it after regulators questioned its safety. The withdrawal happened last Friday in the US. In January, Meridia sales were suspended in Europe.
Kinetic Concepts, Inc. today reported second quarter 2010 total revenue of $497.8 million, an increase of 1% from the second quarter of 2009 and up 2% from the first quarter of 2010. Total revenue for the first half of 2010 was $983.6 million, a 2% increase from the prior-year period. Unfavorable foreign currency exchange movements reduced total revenue for the second quarter of 2010 by less than 1%, while favorably impacting total revenue for the first six months of 2010 by 1% compared to the corresponding periods of the prior year.
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
› Verified 9 days ago